key: cord-0976289-pbukat1k authors: Asai, Nobuhiro; Mikamo, Hiroshige title: COVID-19 disease severity is linked to host immunity as well as lung and gut dysbiosis: a narrative review date: 2021-11-04 journal: J Glob Antimicrob Resist DOI: 10.1016/j.jgar.2021.10.009 sha: 3011cb51691655afe7befeeb3640803d8d5d4f08 doc_id: 976289 cord_uid: pbukat1k nan Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a high pathogenesis and coronavirus disease 2019 (COVID-19) has a high mortality rate of 12-45% among cases with pneumonia requiring intensive care unit admission. Radiological findings of COVID-19 pneumonia can differ with differing host immunity, even though it is the same disease caused by the same pathogen. There are several theories that COVID-19 patients show different radiological patterns and outcomes by age. Not only viral pathogenesis but also dysfunction of monocytes with aging as well as lung and gut dysbiosis could contribute to the high mortality rate in elderly patients. Monocytes play an essential role in the more severe COVID-19 disease that occurs in the elderly. Aging has been reported to be characterised by substantial dysregulation of various cellular functions in monocytes and macrophages. Monocytes isolated from the elderly show increased basal cytokine production compared with monocytes from younger people [1] . In addition, monocytes in the elderly also exhibit impaired phagocytosis and decreased expression of the human leukocyte antigen-DR isotype [2] . We speculate that monocyte dysfunction may contribute to the severity of more disorders of COVID-19 in the elderly. The severity of COVID-19 disease is strongly correlated with gut and lung dysbiosis. The gut microbiome of COVID-19 patients has a significant reduction in bacterial diversity, a significantly higher relative abundance of opportunistic pathogens such as Bacteroides dorei and Akkermansia muciniphila were positively correlated with interleukin 1-beta (IL-1), interleukin 6 (IL-6) and C-X-C motif ligand 8 (CXCL8) [4] . The lung microbiome has several roles in viral immunity. First, microbiota dwelling on the respiratory surface can act as a barrier, therefore preventing viral attachment to host cells. Second, it primes lung immunity, which will fight against viral infection, and exposure to a diverse range of microbiota may build a wider immunity. Focusing on alteration of the microbiota, a reduction in faecal bifidobacteria has often been noted for age-related gut dysbiosis. Besides, a reduction in butyrate-producing organisms from the Clostridium cluster XIVa as well as anti-inflammatory organisms such as Faecalibacterium prausnitzii and Akkermansia muciniphila have been reported [5] . In summary, lung and gut dysbiosis affect the disease severity of COVID-19 and its prognosis. The lung and gut microbiome may soon be a potential therapeutic target for COVID-19. In conclusion, viral immunity affected by lung and gut dysbiosis and age-associated monocyte dysfunction could affect disease severity in humans. We hypothesise that radiological findings and prognosis of COVID-19 differ by age group. Funding: None. Antitumoral properties of aged human monocytes Complex immune dysregulation in COVID-19 patients with severe respiratory failure The lower respiratory tract microbiome of critically ill patients with COVID-19 Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 Gut microbiota and aging Ethical approval: Not required.